



**Clinical Research Trials**

**Last Updated: 06/12/24**

**Monument Health Cancer Care Institute**

<b>Brain</b>	<b>Trial Title</b>	<b>ClinicalTrials.gov Link</b>
None at this time		

<b>Breast</b>	<b>Trial Title</b>	<b>ClinicalTrials.gov Link</b>
Breast (A011801)	The COMPASSHER2 Trials (COMprehensive use of Pathologic Response ASSEssment to Optimize Therapy in HER2-Positive Breast Cancer): COMPASSHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DMI and Placebo Compared with T-DMI and Tucatinib	<a href="https://www.clinicaltrials.gov/study/NCT04457596?id=A011801&amp;rank=1">https://www.clinicaltrials.gov/study/NCT04457596?id=A011801&amp;rank=1</a>
GS-US-595-6184	Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05)	<a href="https://www.clinicaltrials.gov/study/NCT05633654?id=gs-us-595-6184&amp;rank=1">https://www.clinicaltrials.gov/study/NCT05633654?id=gs-us-595-6184&amp;rank=1</a>
NRG-BR009	Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25 (OFSET)	<a href="https://www.clinicaltrials.gov/study/NCT05879926?id=br009&amp;rank=1">https://www.clinicaltrials.gov/study/NCT05879926?id=br009&amp;rank=1</a>
S2010	A randomized phase III trial comparing active symptom monitoring plus patient education versus patient education alone to improve persistence with endocrine therapy in young women with Stage I-III breast cancer (ASPEN)	<a href="https://www.clinicaltrials.gov/search?id=s2010">https://www.clinicaltrials.gov/search?id=s2010</a>

<b>Gastrointestinal (GI)</b>	<b>Trial Title</b>	<b>ClinicalTrials.gov Link</b>
Colon (NRG-GI008)	Colon Adjuvant Chemotherapy Based on Evaluation of residual Disease (CIRCULATE-US)	<a href="https://www.clinicaltrials.gov/search?id=gi008">https://www.clinicaltrials.gov/search?id=gi008</a>
Esophagus (A022102)	Randomized Phase III Trial of mFOLFIRINOX +/- Nivolumab vs FOLFOX +/- Nivolumab for First-Line Treatment of Metastatic HER2-Negative Gastroesophageal Adenocarcinoma	<a href="https://www.clinicaltrials.gov/study/NCT05677490?id=a022102&amp;rank=1">https://www.clinicaltrials.gov/study/NCT05677490?id=a022102&amp;rank=1</a>
Hepatocellular (GI-2008)	A Phase II Randomized Study of Atezolizumab plus Multi-Kinase Inhibitor Versus Multi-Kinase Inhibitor Alone in Subjects with Unresectable, Advanced Hepatocellular Carcinoma Who Previously Received Atezolizumab and Bevacizumab	<a href="https://www.clinicaltrials.gov/search?id=gi-2008">https://www.clinicaltrials.gov/search?id=gi-2008</a>

<b>Genitourinary (GU)</b>
None at this time

<b>Head and Neck</b>	<b>Trial Title</b>
None at this time	

<b>Hematologic</b>	<b>Trial Title</b>	<b>ClinicalTrials.gov Link</b>
Myelodysplastic Syndromes (NHLBI-MDS)	The National Myelodysplastic Syndromes (MDS) Study	<a href="https://www.clinicaltrials.gov/search?id=nhlbi-mds">https://www.clinicaltrials.gov/search?id=nhlbi-mds</a>

Multiple Myeloma (EAA181)	Effective Quadruplet Utilization after Treatment Evaluation (EQUATE): A randomized phase III trial for newly diagnosed Multiple Myeloma not intended for early autologous transplantation	<a href="https://www.clinicaltrials.gov/search?id=eaa181">https://www.clinicaltrials.gov/search?id=eaa181</a>
Lymphoma (S1918)	A Phase II/III Randomized Study of R-miniCHOP with or without Oral Azacitidine (CC-486) in Participants Age 75 Years or Older with Newly Diagnosed Diffuse Large B Cell Lymphoma, Grade IIIb Follicular Lymphoma, Transformed lymphoma, and High-Grade B-cell Lymphomas with MYC and BCL2 and/or BCL6 Rearrangements	<a href="https://www.clinicaltrials.gov/search?id=eaa181">https://www.clinicaltrials.gov/search?id=eaa181</a>

<b>Lung</b>		<b>ClinicalTrials.gov Link</b>
Small Cell (JZP712-402)	Phase IV Zepzelca Observational Study in Extensive Stage SCLC	<a href="https://www.clinicaltrials.gov/search?id=jzp712-402">https://www.clinicaltrials.gov/search?id=jzp712-402</a>
Non-Small Cell (LUNGMAP)	A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (LUNG-MAP Screening Study)	<a href="https://www.clinicaltrials.gov/search?id=LUNGMAP">https://www.clinicaltrials.gov/search?id=LUNGMAP</a>
Non-Small Cell (S1900G)	A randomized phase II study of INC280 (capmatinib) plus Osimertinib with or without Ramucirumab in participants with EGFR-mutant, MET-amplified stage IV or recurrent NSCLC (LUNG-MAP Sub-Study)	<a href="https://www.clinicaltrials.gov/search?id=S1900g">https://www.clinicaltrials.gov/search?id=S1900g</a>
Non-Small Cell (S2302)	A prospective randomized study of Ramucirumab plus Pembrolizumab versus standard of care for participants previously treated with immunotherapy for stage IV or recurrent non-small cell lung cancer	<a href="https://www.clinicaltrials.gov/search?id=s2302">https://www.clinicaltrials.gov/search?id=s2302</a>
Non-Small Cell (EA5182)	Randomized Phase 3 Study of Combination AZD9291 (osimertinib) and Bevacizumab versus AZD9291 (osimertinib) Alone as First-Line Treatment for Patients with Metastatic EGFR-Mutant Lung Cancer	<a href="https://www.clinicaltrials.gov/search?id=EA5182">https://www.clinicaltrials.gov/search?id=EA5182</a>
<b>Melanoma</b>		<b>ClinicalTrials.gov Link</b>
Melanoma (EA6141)	Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma	<a href="https://www.clinicaltrials.gov/search?id=ea6141">https://www.clinicaltrials.gov/search?id=ea6141</a>
<b>Symptom Management/Other</b>		<b>ClinicalTrials.gov Link</b>
Anorexia (A222004)	A Randomized Phase III Trial of Olanzapine versus Megestrol Acetate for Cancer-Associated Anorexia	<a href="https://www.clinicaltrials.gov/search?id=a222004">https://www.clinicaltrials.gov/search?id=a222004</a>